ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
Published version of a preprint
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in drug development. Here, we report on ProTargetMiner as a publicly available expandable proteome signature library of anticancer molecules in cancer cell lines. Based on 287 A549 adenocarcinoma proteomes affected by 56 compounds, the main dataset contains 7,328 proteins and 1,307,859 refined protein-drug pairs. These proteomic signatures cluster by compound targets and action mechanisms. The targets and mechanistic proteins are deconvoluted by partial least square modeling, provided through the website http://protargetminer.genexplain.com . For 9 molecules representing the most diverse mechanisms and the common cancer cell lines MCF-7, RKO and A549, deep proteome datasets are obtained. Combining data from the three cell lines highlights common drug targets and cell-specific differences. The database can be easily extended and merged with new compound signatures. ProTargetMiner serves as a chemical proteomics resource for the cancer research community, and can become a valuable tool in drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, because most FDA-approved drugs target proteins and protein and RNA levels often correlate weakly, protein-level changes are likely to provide the more relevant readout of compound action (8, 9, 10, 11).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists
Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-48 · Cited by 3,356
On the Dependency of Cellular Protein Levels on mRNA Abundance
Liu, Y., Beyer, A., & Aebersold, R. (2016) · Cell · doi:10.1016/j.cell.2016.03.014 · Cited by 3,221
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification
Bylesjö, M., Rantalainen, M., Cloarec, O., Nicholson, J. K., Holmes, E., & Trygg, J. (2006) · Journal of Chemometrics · doi:10.1002/cem.1006 · Cited by 1,475
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Research works printed but not linked: 50
- Hughes, T. R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109–126 (2000). · DOI · Paper page
- Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109 (2016). · DOI · Paper page
- Readhead, B. et al. Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. Nat. Commun. 9, 4412 (2018). · DOI · Paper page
- Litichevskiy, L. et al. A library of phosphoproteomic and chromatin signatures for characterizing cellular responses to drug perturbations. Cell Syst. 6, 424–443 e427 (2018). · DOI · Paper page
- Savitski, M. M. et al. Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis. Cell 173, 260–274 e225 (2018). · DOI · Paper page
- Hausser, J., Mayo, A., Keren, L. & Alon, U. Central dogma rates and the trade-off between precision and economy in gene expression. Nat. Commun. 10, 68 (2019). · DOI · Paper page
- Nuñez, G., Benedict, M. A., Hu, Y. & Inohara, N. Caspases: the proteases of the apoptotic pathway. Oncogene 17, 3237–3245 (1998). · DOI · Paper page
- Kwon H. J., Karuso P. Chemical proteomics, an integrated research engine for exploring drug-target-phenotype interactions. Proteome Sci 16 https://doi.org/10.1186/s12953-017-0129-x (2018). · DOI
- Barglow, K. T. & Cravatt, B. F. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 4, 822 (2007). · DOI · Paper page
- Rix, U. & Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616 (2009). · DOI · Paper page
- Saei, A. A. et al. Comparative proteomics of dying and surviving cancer cells improves the identification of drug targets and sheds light on cell life/death decisions. Mol. Cell Proteom. 17, 1144–1155 (2018). · DOI
- Browne, C. M. et al. A chemoproteomic strategy for direct and proteome-wide covalent inhibitor target-site identification. J. Am. Chem. Soc. 141, 191–203 (2018). · DOI · Paper page
- Chernobrovkin, A., Marin-Vicente, C., Visa, N. & Zubarev, R. A. Functional identification of target by expression proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs. Sci. Rep. 5, 11176 (2015). · DOI
- Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511–1516 (2008). · DOI · Paper page
- Palmer, A. C. & Kishony, R. Opposing effects of target overexpression reveal drug mechanisms. Nat. Commun. 5, 4296 (2014). · DOI
- Daum, G., Lees, N. D., Bard, M. & Dickson, R. Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 14, 1471–1510 (1998). · DOI · Paper page
- Lee, R. F. et al. Expression proteomics study to determine metallodrug targets and optimal drug combinations. Sci. Rep. 7, 1590 (2017). · DOI
- Tarasova, N. K. et al. Cytotoxic and proinflammatory effects of metal-based nanoparticles on THP-1 monocytes characterized by combined proteomics approaches. J. Proteome Res. 16, 689–697 (2016). · DOI
- Maaten, Lvd & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn Res. 9, 2579–2605 (2008).
- Zhang, X. et al. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage. Biochem. Pharmacol. 156, 291–301 (2018). · DOI
- Stafford, W. C. et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci. Transl. Med. 10, eaaf7444 (2018). · DOI · Paper page
- da Silva, D. C., Andrade, P. B., Valentão, P. & Pereira, D. M. Neurotoxicity of the steroidal alkaloids tomatine and tomatidine is RIP1 kinase-and caspase-independent and involves the eIF2α branch of the endoplasmic reticulum. J. Steroid Biochem. Mol. Biol. 171, 178–186 (2017). · DOI
- Roddick, J. G. & Drysdale, R. Destabilization of liposome membranes by the steroidal glycoalkaloid α-tomatine. Phytochemistry 23, 543–547 (1984). · DOI
- Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907–4916 (2006). · DOI · Paper page
- Hillert, E.-K. et al. Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation. Cancer Lett. 448, 70–83 (2019). · DOI
- Liu, N. et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 5, 5453 (2014). · DOI · Paper page
- Zhang, X. et al. Repurposing of auranofin: thioredoxin reductase remains a primary target of the drug. Biochimie 162, 46–54 (2019). · DOI · Paper page
- Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957–967 (1993). · DOI · Paper page
- Marin-Vicente, C., Lyutvinskiy, Y., Romans Fuertes, P., Zubarev, R. A. & Visa, N. The effects of 5-fluorouracil on the proteome of colon cancer cells. J. Proteome Res. 12, 1969–1979 (2013). · DOI
- Bruno, P. M. et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat. Med. 23, 461 (2017). · DOI · Paper page
- Triba, M. N. et al. PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol. Biosyst. 11, 13–19 (2015). · DOI · Paper page
- Galindo‐Prieto, B., Eriksson, L. & Trygg, J. Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS). J. Chemom. 28, 623–632 (2014). · DOI · Paper page
- Horwitz, S. B. Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 5, S3–S6 (1994). · DOI
- Himes, R. H., Kersey, R. N., Heller-Bettinger, I. & Samson, F. E. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 36, 3798–3802 (1976).
- Bull, V. H., Rajalingam, K. & Thiede, B. Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. J. Proteome Res. 11, 1609–1620 (2012). · DOI
- Doherty, K. R. et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol. Appl. Pharmacol. 272, 245–255 (2013). · DOI · Paper page
- Widatalla, S. E. et al. Lapatinib induced Annexin A6 up-regulation as an adaptive response of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. Carcinogenesis 40, 998–1009 (2018). · DOI
- Tassi, R., Baldazzi, V., Lapini, A., Carini, M. & Mazzanti, R. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events? Clin. Genitourin. Cancer 13, e101–e105 (2015). · DOI
- Jensen, B. C. et al. Non-targeted metabolomics analysis of the effects of tyrosine kinase inhibitors sunitinib and erlotinib on heart, muscle, liver and serum metabolism in vivo. Metabolites 7, 31 (2017). · DOI
- Ezzoukhry, Z. et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int. J. Cancer 131, 2961–2969 (2012). · DOI · Paper page
- Wang, L. et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab. Dispos. 36, 1828–1839 (2008). · DOI
- Arastu-Kapur, S. et al. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 17, 2734–2743 (2011). · DOI · Paper page
- Chernobrovkin, A. L. & Zubarev, R. A. How well can morphology assess cell death modality? A proteomics study. Cell Death Discov. 2, 16068 (2016). · DOI
- Good, D. M. & Zubarev, R. A. Drug target identification from protein dynamics using quantitative pathway analysis. J. Proteome Res. 10, 2679–2683 (2011). · doi:10.1021/pr200090m
- Wagner, E. K. & Roizman, B. Effect of the vinca alkaloids on RNA synthesis in human cells in vitro. Science 162, 569–570 (1968). · doi:10.1126/science.162.3853.569
- Sabatier, P., Saei, A. A., Wang, S. & Zubarev, R. A. Dynamic proteomics reveals high plasticity of cellular proteome: growth-related and drug-induced changes in cancer cells are comparable. Proteomics 18, 1800118 (2018). · DOI
- Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized ppb-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367 (2008). · DOI · Paper page
- Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011). · DOI · Paper page
- Veselkov, K. A. et al. Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal. Chem. 83, 5864–5872 (2011). · DOI · Paper page
- Vizcaíno, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223 (2014). · DOI · Paper page
Cited by
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Self-citation
Metadata
- Authors
- Saei, A. A., Beusch, C. M., Chernobrovkin, A., Sabatier, P., Zhang, B., Tokat, Ü. G., Stergiou, E., Gaetani, M., Végvári, Á., & Zubarev, R. A.
- ORCID
- Venue
- Nature Communications
- Published
- 2019-12-16
- Volume
- 10
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 81
- References
- 18
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Cancerfonden (2016/546, 2017/1081)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. https://app.cochat.ai/papers/10.1038/s41467-019-13582-8
- The paper
- Saei, A. A., Beusch, C. M., Chernobrovkin, A., Sabatier, P., Zhang, B., Tokat, Ü. G., Stergiou, E., Gaetani, M., Végvári, Á., & Zubarev, R. A. (2019). ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. Nature Communications. https://doi.org/10.1038/s41467-019-13582-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.